Varghese, Abraham M <br/><br/>
Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.  [electronic resource] 

 -  British journal of haematology  02 2017 
 - 573-582 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2141 
<br/><br/><label>Standard No.: </label>10.1111/bjh.14342  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Alemtuzumab<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Bone Marrow Examination<br/>Consolidation Chemotherapy<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm, Residual--drug therapy<br/>Recurrence<br/>Survival Rate<br/>Treatment Outcome